Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage progr... Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.265 | -8.89261744966 | 2.98 | 3.03 | 2.67 | 5372761 | 2.89047349 | CS |
4 | -0.085 | -3.03571428571 | 2.8 | 3.1475 | 2.622 | 2788761 | 2.90996422 | CS |
12 | 0.375 | 16.0256410256 | 2.34 | 3.45 | 2.1 | 2345331 | 2.83569086 | CS |
26 | 0.505 | 22.850678733 | 2.21 | 3.45 | 1.74 | 2008176 | 2.57712974 | CS |
52 | 0.475 | 21.2053571429 | 2.24 | 3.45 | 1.51 | 1489278 | 2.39620949 | CS |
156 | -18.255 | -87.0529327611 | 20.97 | 22.94 | 1.51 | 948299 | 4.43138532 | CS |
260 | -13.185 | -82.9245283019 | 15.9 | 24.47 | 1.51 | 922615 | 4.95253544 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.